Company / Current Liabilities
Ultragenyx Pharmaceutical Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$384.0M
FY2025
5-year range
$181.4M / $384.0M
FY2021-FY2025
Trend
+11.6%
vs FY2024
Sector context
#40 of 213
Health Care
What the data says
Ultragenyx Pharmaceutical Inc.'s current liabilities of $384M is higher than 81% of companies in the Health Care sector (FY2025). Current Liabilities has increased for 4 consecutive years, from $181M in FY2021 to $384M in FY2025.
Based on SEC 10-K filings.
$384M in FY2025 with a 5-year CAGR of +15.2%. Top quartile in the Health Care sector.
Increased from $280M to $384M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +13.7%
- 5-Year CAGR
- +15.2%
- 10-Year CAGR
- -
Sector benchmark
-75.8% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s current liabilities has grown for 4 consecutive years.
- 5-year CAGR of +15.2%, indicating consistent growth.
- In FY2025, current liabilities increased 11.6% year-over-year.
- Ranks #40 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $384.0M | +11.6% |
| FY2024 | $344.0M | +22.7% |
| FY2023 | $280.4M | +7.4% |
| FY2022 | $261.2M | +44.0% |
| FY2021 | $181.4M | -4.3% |
| FY2020 | $189.6M | +83.6% |
| FY2019 | $103.3M | +38.2% |
| FY2018 | $74.7M | +5.2% |
| FY2017 | $71.0M | +17.8% |
| FY2016 | $60.3M | +115.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026